Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
The SURMOUNT-1 trial (tirzepatide, published in NEJM 2022) demonstrated that participants with obesity or overweight without diabetes who received tirzepatide experienced weight reductions of 16.0% (5mg), 21.4% (10mg), and 22.5% (15mg) over 72 weeks
These medications are particularly effective when combined with physical activity and a calorie-controlled diet
For example, Black Americans are 77% more likely to be diagnosed with diabetes compared to their white counterparts
Table of Contents The Rise of GLP-1 Injection in India: Weight Loss, Reimagined Understanding the Disruption in the Fitness Industry But why all the buzz
Unlike a generic "GLP-1 friendly" label, a dietitian has the knowledge to personalize recommendations to every patient.
Water retention Some puffiness or bloating, especially in hands and face, as IGF-1 causes cells to hold more water
